Akay, M;
Funingana, I-G;
Patel, G;
Mustapha, R;
Gjafa, E;
Ng, T;
Ng, K;
(2021)
An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions.
Oncology and Therapy
10.1007/s40487-021-00167-z.
(In press).
Preview |
Text
Akay2021_Article_AnIn-DepthReviewOfNiraparibInO.pdf - Published Version Download (1MB) | Preview |
Abstract
Niraparib is an oral, potent, highly selective poly-ADP ribose polymerase 1 (PARP1) and PARP2 inhibitor. In most developed countries, it is approved as a maintenance treatment for epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients with complete or partial response to platinum-based therapy. These approvals are based on results of randomised, double-blind, placebo-controlled trials, particularly the NOVA trial and more recently the PRIMA trial. In this comprehensive review, we delve into the scientific basis of PARP inhibition, discussing both preclinical and clinical data which have led to the current approval status of niraparib. We also discuss ongoing trials and biological rationale of combination treatments involving niraparib, with particular focus on antiangiogenic drugs, immune checkpoint inhibitors and cyclic GMP-AMP synthase stimulator of interferon genes (cGAS/STING) pathway. In addition, we reflect on potential strategies and challenges of utilising current biomarkers for treatment selection of patients to ensure maximal benefit.
Type: | Article |
---|---|
Title: | An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1007/s40487-021-00167-z |
Publisher version: | https://doi.org/10.1007/s40487-021-00167-z |
Language: | English |
Additional information: | © 2021 Springer Nature Switzerland AG. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/). |
Keywords: | Combined therapy, Niraparib, Ovarian Cancer ,PARP inhibitors Pharmacokinetics |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
URI: | https://discovery.ucl.ac.uk/id/eprint/10132853 |
Archive Staff Only
View Item |